Agnieszka Jagiello-Gruszfeld
Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandPublications
-
Research Article
Author(s): Karolina Miacz47822, Agnieszka Jagiello-Gruszfeld47823*, Michal Kunkiel47824, Izabela Lemanska47825, Anna Gorniak47826, Zbigniew Nowecki47827 and Anna Niwinska47828
Human Epidermal growth factor Receptor-2 (HER-2) overexpression can be found in 15%-20% of Breast Cancers (BC), and it strongly correlates with aggressive clinical behavior and adverse prognosis. The first- line treatment for HER-2 positive Metastatic Breast Cancers is the combination of trastuzumab, pertuzumab, and taxane (PTH). ABP 980 is a biosimilar of the innovator trastuzumab and is characterized by highly comparable effectiveness. The group of 61 patients with HER-2 positive Metastatic Breast Cancer MBC received biosimilar ABP 980 plus pertuzumab and docetaxel from November, 18, 2018 to December, 24, 2019. The response to therapy, Overall Survival (OS), Progression-Free Survival (PFS), metastases, and adverse effects among patients were determined and analyzed. Initially, 42 women responded partially to the treatment and their median PFS was 27 months. Median PFS for .. Read More»
DOI: 10.31858/0975-8453.13.11.785-793